GIP stands for glucose-dependent insulinotropic polypeptide. Retatrutide and tirzepatide both engage the GIP receptor as part of a multi-receptor design.
GIP within a multi-receptor design
To isolate the role of GIP in a clinical outcome, researchers would need a comparison that holds other relevant aspects of the molecules constant. Typical obesity trials compare complete interventions.
How to interpret the evidence
Treat a claim about the contribution of GIP as a mechanism hypothesis unless the design specifically tests it.
Start with the intervention name and receptor targets, then follow the links to the original trial if you want to check what was measured in people.